Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Publication ,  Journal Article
Mor, A; Bingham, CO; Barisoni, L; Lydon, E; Belmont, HM
Published in: The Journal of Rheumatology
April 2005

Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.

Duke Scholars

Published In

The Journal of Rheumatology

ISSN

0315-162X

Publication Date

April 2005

Volume

32

Issue

4

Start / End Page

740 / 743

Related Subject Headings

  • Withholding Treatment
  • Vasculitis, Leukocytoclastic, Cutaneous
  • Recombinant Fusion Proteins
  • Receptors, Tumor Necrosis Factor
  • Lupus Nephritis
  • Immunoglobulin G
  • Immunocompromised Host
  • Humans
  • Female
  • Etanercept
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mor, A., Bingham, C. O., Barisoni, L., Lydon, E., & Belmont, H. M. (2005). Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. The Journal of Rheumatology, 32(4), 740–743.
Mor, Adam, Clifton O. Bingham, Laura Barisoni, Eileen Lydon, and H Michael Belmont. “Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.The Journal of Rheumatology 32, no. 4 (April 2005): 740–43.
Mor A, Bingham CO, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. The Journal of Rheumatology. 2005 Apr;32(4):740–3.
Mor, Adam, et al. “Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.The Journal of Rheumatology, vol. 32, no. 4, Apr. 2005, pp. 740–43.
Mor A, Bingham CO, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. The Journal of Rheumatology. 2005 Apr;32(4):740–743.

Published In

The Journal of Rheumatology

ISSN

0315-162X

Publication Date

April 2005

Volume

32

Issue

4

Start / End Page

740 / 743

Related Subject Headings

  • Withholding Treatment
  • Vasculitis, Leukocytoclastic, Cutaneous
  • Recombinant Fusion Proteins
  • Receptors, Tumor Necrosis Factor
  • Lupus Nephritis
  • Immunoglobulin G
  • Immunocompromised Host
  • Humans
  • Female
  • Etanercept